Rapamycin (Sirolimus) Off-Label Use in Adolescents Ages 12 to 17: What the Evidence Shows

What Is Sirolimus and Why Is It Used Off-Label in Adolescents?

Sirolimus is a macrolide antibiotic derivative that inhibits mTOR complex 1, a serine/threonine kinase that controls cell growth, protein synthesis, and autophagy. The FDA approved sirolimus for kidney-transplant rejection prophylaxis in 1999, and the label specifically includes patients aged 13 years and older at low-to-moderate immunologic risk [1]. Off-label use in adolescents has grown steadily over the past two decades because several rare diseases in this age group are driven by hyperactivated mTOR signaling.

The mTOR Pathway in Adolescent Disease

Tuberous sclerosis complex results from loss-of-function mutations in TSC1 or TSC2, both of which normally suppress mTORC1. Without that suppression, mTOR runs continuously, producing the benign tumors (hamartomas) that appear in the brain, kidneys, lungs, and skin. Sirolimus directly targets this overactive pathway. In a 2013 randomized trial published in The Lancet (N=117 pediatric and adult patients), everolimus (a sirolimus analog) reduced subependymal giant-cell astrocytoma volume by 50% or more in 35% of participants versus 0% on placebo (P<0.001) [2]. That result catalyzed broad interest in mTOR inhibition for TSC across all age groups.

Vascular Anomalies and PIK3CA-Related Overgrowth

The PIK3CA-related overgrowth spectrum (PROS) and many vascular malformations also involve upstream PI3K/AKT/mTOR activation. A 2019 prospective series in NEJM (N=19 patients with PROS, median age 13 years) showed that alpelisib (a PI3K inhibitor) reduced overgrowth volume, but sirolimus is more accessible and has been used in practice for years before targeted PI3K agents were available [3]. Multiple case series document partial but meaningful responses to sirolimus in kaposiform hemangioendothelioma and complex lymphatic malformations, conditions that appear predominantly in children and adolescents [4].

FDA Label Boundaries for Adolescents: What Is and Is Not Approved

The approved population for sirolimus begins at age 13. Below that threshold, use is entirely off-label. Within the 13-to-17 age band, the label covers one specific scenario: renal allograft recipients at low-to-moderate immunologic risk who can tolerate calcineurin inhibitor withdrawal after 2 to 4 months [1].

Approved Dosing for Adolescent Transplant Recipients

The prescribing information specifies a loading dose of 3 mg/m² on day 1, followed by a maintenance dose of 1 mg/m² per day. Trough concentrations should be maintained between 4 and 12 ng/mL when sirolimus is used without cyclosporine, and between 4 and 8 ng/mL during the cyclosporine co-administration period [1]. Body surface area-based dosing is preferred over flat milligram dosing in adolescents because pharmacokinetic variability is higher in this age group than in adults.

What Falls Outside the Label

Any use in adolescents for tuberous sclerosis complex seizure control, SEGA treatment, vascular malformations, lymphangioleiomyomatosis, or longevity/anti-aging purposes is off-label. This does not mean these uses are clinically irrational, but it does mean the prescribing physician assumes the full burden of informed consent documentation, individualized benefit-risk analysis, and monitoring protocol design.

Off-Label Indications With Clinical Evidence in Adolescents

Tuberous Sclerosis Complex

TSC is the best-supported off-label indication for mTOR inhibitors in adolescents. The 2012 EXIST-1 trial (N=117) showed that everolimus at a trough of 5 to 15 ng/mL reduced SEGA volume by 50% or more in 35% of patients at 24 weeks, with no complete responses in the placebo group [2]. While everolimus now carries its own FDA approval for TSC indications including SEGA and renal angiomyolipoma, sirolimus is used interchangeably in clinical practice when formulary or cost considerations arise. A 2011 open-label study by Franz et al. (N=36, ages 3 to 34 years) showed that sirolimus at troughs of 5 to 15 ng/mL reduced SEGA volume in 32 of 36 patients over 24 months, with a median reduction of 29.3% [5].

TSC clinical guidelines from the Tuberous Sclerosis Alliance and the European Reference Network recommend mTOR inhibitor therapy for growing SEGA, symptomatic angiomyolipoma larger than 3 cm, and TSC-associated pulmonary lymphangioleiomyomatosis [6].

Vascular Anomalies

Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon represents one of the more compelling pediatric use cases. A 2018 retrospective series published in the Journal of Pediatric Surgery (N=27 patients, median age 8 months to 14 years) reported platelet normalization in 19 of 27 patients and lesion stabilization or reduction in 22 of 27 after sirolimus initiation at 0.8 mg/m² twice daily, targeting troughs of 10 to 15 ng/mL [4]. Responses typically appeared within 4 to 8 weeks.

Complex lymphatic malformations, including diffuse lymphangiomatosis and Gorham-Stout disease, have been treated with sirolimus in single-center series and case reports. Responses are partial and inconsistent, but the disease burden is high enough that clinicians consider the risk acceptable when surgical options are exhausted.

PTEN Hamartoma Tumor Syndrome

PTEN loss activates the same PI3K/AKT/mTOR axis as TSC mutations. In adolescents with Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome who develop symptomatic hamartomas, sirolimus has been used off-label. Prospective data are absent, but the mechanistic rationale is clear and supported by preclinical models [7].

Dosing Considerations Specific to Adolescents

Pharmacokinetics in the 12-to-17 Age Group

Adolescents show greater intraindividual pharmacokinetic variability than adults. The oral bioavailability of sirolimus averages about 15%, and half-life is approximately 62 hours in adults, but pediatric data suggest a shorter half-life closer to 40 to 50 hours in younger patients, meaning trough accumulation takes longer and steady-state is reached later [1]. Dose adjustments are almost always needed in the first 4 to 6 weeks.

Weight-based and BSA-based calculations are both used. For non-transplant indications such as TSC, many centers start at 0.5 to 1 mg/m² per day and titrate to a target trough of 5 to 10 ng/mL, checking levels every 2 weeks until two consecutive troughs fall within range.

Drug-Drug Interactions

Sirolimus is a narrow-therapeutic-index CYP3A4 and P-glycoprotein substrate. Adolescents taking azole antifungals (fluconazole, voriconazole) for infections following immunosuppression may see sirolimus troughs rise 3- to 10-fold within days. St. John's wort can reduce troughs by more than 50%. These interactions require close trough monitoring and often temporary dose holds rather than empiric reductions.

Safety Profile in Adolescents: What Differs From Adults

Immunosuppression and Infection Risk

Sirolimus blunts T-cell proliferation and cytokine production. In adolescent transplant recipients, the RAPTOR and RAPAMUNE key trials (adult-predominant populations) documented a 30-day serious infection rate of roughly 8% at full immunosuppressive doses [1]. Adolescents in non-transplant settings typically receive lower troughs (5 to 10 ng/mL), which carries a lower absolute infection burden, but the risk is not zero. Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole is standard for the first 12 months.

Lipid and Metabolic Effects

Hyperlipidemia occurs in 45 to 57% of sirolimus-treated patients in transplant trials [1]. Adolescents present a specific concern because dyslipidemia during this developmental window may have long-term cardiovascular consequences. Fasting lipid panels should be checked at baseline, 4 weeks, 12 weeks, and every 3 months thereafter. If LDL-C exceeds 160 mg/dL despite dietary modification, statin therapy should be considered.

Menstrual and Reproductive Effects

Female adolescents may experience menstrual irregularity on sirolimus. The mechanism likely involves mTOR's role in follicular development. Case reports and small series describe amenorrhea in 10 to 20% of women on long-term sirolimus at transplant doses [8]. Fertility effects at sub-immunosuppressive doses are not well characterized. Clinicians prescribing to female adolescents should document menstrual history at baseline and re-assess at each visit.

Growth and Bone Health

MTOR signaling is integral to growth-plate chondrocyte function and longitudinal bone growth. Animal data raise the possibility that sustained mTOR inhibition during adolescent growth could affect final height. Human data in transplant patients are confounded by concurrent steroid use. A 2019 registry analysis of pediatric TSC patients on mTOR inhibitors found no statistically significant reduction in height-for-age Z-scores over 24 months, but the follow-up was short and the sample size limited to 48 patients [9]. Growth monitoring (height, weight, and Tanner staging) every 6 months is a reasonable minimum.

Longevity and Anti-Aging Use: The Evidence Gap in Adolescents

Rapamycin has attracted significant attention for potential longevity applications in adults, largely based on the 2009 NIA Interventions Testing Program study showing a 9 to 14% lifespan extension in genetically heterogeneous mice when sirolimus was introduced at 600 days of age (equivalent to roughly 60 human years) [10]. Observational data from the PEARL trial and Dog Aging Project have extended interest to human and companion-animal studies.

None of this work involves adolescent or young-adult populations. The NIA ITP data actually suggest the survival benefit is attenuated when mTOR inhibition begins at younger ages in mice. A 2022 analysis in Cell (N=not a human trial, but a multi-cohort mouse study) found that early-life rapamycin reduced cancer incidence but also suppressed immune memory formation, raising the concern that immunological imprinting during development could be compromised [11].

The American Academy of Pediatrics has not issued a formal position on rapamycin for longevity in adolescents, but the broader framework from the Society for Adolescent Health and Medicine is unambiguous: off-label prescribing in minors requires a demonstrated clinical indication, a favorable benefit-to-risk ratio specific to the developmental stage, and documented informed consent from both the patient and a guardian [12].

Prescribing rapamycin to a healthy adolescent for life-extension purposes has no published trial support, no regulatory basis, and an unfavorable risk profile given the immunosuppressive, metabolic, and potentially growth-related effects outlined above.

Monitoring Protocol for Off-Label Adolescent Use

Regardless of indication, a structured monitoring protocol is necessary whenever sirolimus is prescribed off-label to a patient aged 12 to 17.

Baseline Workup

Before the first dose, obtain: complete blood count with differential, comprehensive metabolic panel, fasting lipid panel, urine protein-to-creatinine ratio, sirolimus trough (if transitioning from another mTOR inhibitor), height and weight with Tanner staging, and pregnancy test in all females of reproductive potential.

On-Treatment Monitoring Schedule

• Sirolimus trough: weeks 2, 4, 8, and 12, then every 3 months once stable
• CBC and metabolic panel: every 4 weeks for the first 3 months, then quarterly
• Fasting lipid panel: weeks 4 and 12, then every 3 months
• Urinalysis with protein: every 3 months
• Height, weight, Tanner stage: every 6 months
• Annual ophthalmology if on TSC indication (retinal hamartoma surveillance)

Stopping Rules

Hold sirolimus and obtain urgent trough if any of the following occur: new fever with absolute neutrophil count <1,000/µL, serum creatinine rise of more than 30% above baseline without alternative explanation, new-onset proteinuria above 1 g/day, or interstitial lung changes on imaging. Rapamycin-associated pneumonitis is rare at low doses but has been reported in pediatric TSC patients and requires prompt recognition [5].

Informed Consent Requirements for Adolescent Off-Label Prescribing

Off-label prescribing in minors carries distinct legal and ethical obligations. The FDA's 2014 pediatric off-label guidance states that prescribing outside approved indications is not inherently prohibited, but documentation of the clinical rationale, the alternatives considered, and the risk-benefit discussion must appear in the medical record [13].

For adolescents between 12 and 17, the consent process should include both the parent or legal guardian and the patient. Depending on state law, a minor aged 14 or older may have the right to participate meaningfully in treatment decisions. The Society for Adolescent Health and Medicine recommends "developmentally appropriate assent" as a standard, meaning the adolescent is given an explanation matching their cognitive and emotional level, not just a signature page [12].

A sample consent discussion should cover: the FDA-approved indication versus the proposed use, the expected benefit based on available evidence, the common side effects (infection, hyperlipidemia, wound-healing impairment), the uncertain effects on growth and reproductive function, the monitoring requirements, and the plan for discontinuation if the drug is not tolerated or not effective.

Practical Prescribing Summary for Clinicians

Sirolimus in adolescents aged 12 to 17 is a narrow-use drug. The approved indication (renal transplant rejection prophylaxis from age 13) is supported by pharmacokinetic and efficacy data. The best-supported off-label indication is TSC, where mTOR inhibitor therapy has Class I evidence from EXIST-1 and supporting open-label data from the Franz et al. Series [2, 5].

For vascular anomalies, the evidence base is smaller and largely retrospective, but several series with 20 to 40 patients document meaningful responses at troughs of 10 to 15 ng/mL. For PTEN syndromes, the mechanistic rationale is solid but prospective data are absent.

Longevity use in healthy adolescents is not supported by any published clinical evidence and should not be initiated outside a formally approved institutional research protocol.

The monitoring framework above should be treated as a minimum standard. Any prescribing physician should expect to track trough levels, metabolic parameters, and growth at regular intervals for the duration of therapy, and should document each benefit-risk reassessment in the medical record.

The 2023 TSC international guidelines recommend mTOR inhibitor therapy for SEGA with documented growth rate exceeding 0.5 cm/year in any dimension, a threshold that provides an objective trigger for initiating and maintaining sirolimus at a trough of 5 to 10 ng/mL in adolescents [6].